BioSpace News Archive

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®20717, a PD-1 x CTLA-4 bispecific antibody and Xencor’s first tumor microenvironment activator, in patients with advanced solid tumors (DUET-2).

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results from two of its investigational pipeline molecules.

Psychemedics Corporation announced first quarter financial results for the period ended March 31, 2020.

Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, announced that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Virtual Conference as follows:

Black Diamond Therapeutics, Inc. announced that the design of MasterKey-01, the Company’s first-in-human Phase 1/2 clinical trial for its lead product candidate BDTX-189, will be presented as a poster presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program, taking place from May 29-31, 2020.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 1,800,000 of its Class A common shares.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT5528 will be presented during an e-poster session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program on May 29-31, 2020

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced further details of oral and poster presentations at the American Society of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program taking place from May 29 - May 31, 2020.